Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened

Key Points

• Scholar Rock shares fell 7.1% to $48.18 despite the FDA’s approval of ISEMBYLD, its spinal muscular atrophy treatment. The decline appears to reflect profit-taking and investor concerns about valuation and the challenges of commercial execution.
• Analysts generally remain positive, with a consensus “Moderate Buy” rating and an average price target of $66.00; Wedbush, JPMorgan and BMO recently set targets ranging from $63 to $84. However, Barclays downgraded the stock to “cautious.”
• ISEMBYLD carries a list price of $11,659 per vial and an estimated annual treatment cost of about $310,000, creating significant revenue potential while making reimbursement, affordability and payer access key launch risks.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) was down 7.1% during mid-day trading on Tuesday . The company traded as low as $46.54 and last traded at $48.1750. Approximately 716,509 shares traded hands during trading, a decline of 46% from the average daily volume of 1,323,648 shares. The stock had previously closed at $51.85.

Scholar Rock News Roundup

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: The FDA approved ISEMBYLD for the treatment of spinal muscular atrophy (SMA) in children and adults. Scholar Rock describes it as the first therapy designed to directly target the muscle loss associated with SMA, expanding the company from a clinical-stage biotechnology business toward commercialization. Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell
• Positive Sentiment: Analysts viewed the early approval as a positive surprise. UBS reportedly maintained a constructive outlook, while Wedbush reaffirmed its “outperform” rating and set a $64 price target, implying substantial upside from recent trading levels. Other reports cited a consensus “Buy” recommendation. Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as Positive Surprise, UBS Says
• Positive Sentiment: Wall Street raised price targets following the approval, reflecting expectations that ISEMBYLD could generate meaningful revenue in the SMA market and provide a differentiated treatment option. SRRK Shares Pull Back After FDA Approval for Genetic Disease Drug — But Wall Street Hikes Price Targets
• Neutral Sentiment: Scholar Rock set a list price of $11,659 per single-use vial, with an estimated annual treatment cost of approximately $310,000. The pricing supports significant potential revenue per patient but makes reimbursement, affordability and payer access important launch risks. Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
• Negative Sentiment: Despite the approval-driven rally, shares decreased as investors appeared to take profits and reassess the stock’s valuation and commercial execution requirements. The pullback suggests the approval was already partly anticipated and that near-term focus has shifted to launch uptake, reimbursement and sales performance.

Wall Street Analyst Weigh In

SRRK has been the subject of a number of recent research reports. Barclays downgraded shares of Scholar Rock from an "overweight" rating to a "cautious" rating in a research note on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Scholar Rock in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their price target on Scholar Rock from $56.00 to $63.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th. BMO Capital Markets set a $84.00 price objective on Scholar Rock in a research note on Monday. Finally, Wedbush reaffirmed an "outperform" rating and set a $64.00 price objective on shares of Scholar Rock in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Scholar Rock has a consensus rating of "Moderate Buy" and an average price target of $66.00.

Scholar Rock Price Performance

The company has a market cap of $5.72 billion, a PE ratio of -13.63 and a beta of 0.67. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. The stock's 50-day moving average is $53.49 and its 200 day moving average is $49.57.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.84). During the same quarter in the previous year, the business earned ($0.98) earnings per share. On average, equities analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Kristina Burow sold 3,053 shares of the company's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the transaction, the director directly owned 114,657 shares of the company's stock, valued at $6,161,667.18. This represents a 2.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the sale, the director owned 59,511 shares of the company's stock, valued at approximately $3,205,857.57. This trade represents a 4.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 17,149 shares of company stock worth $923,108 over the last quarter. Company insiders own 10.30% of the company's stock.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently modified their holdings of SRRK. BlackRock Inc. purchased a new stake in shares of Scholar Rock in the 2nd quarter valued at $522,175,000. Redmile Group LLC raised its holdings in shares of Scholar Rock by 73.7% during the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company's stock worth $445,715,000 after purchasing an additional 3,845,775 shares during the last quarter. Jennison Associates LLC lifted its position in Scholar Rock by 19.5% during the first quarter. Jennison Associates LLC now owns 3,340,492 shares of the company's stock valued at $164,219,000 after purchasing an additional 545,304 shares during the period. Jupiter Topco LLC acquired a new position in Scholar Rock during the second quarter valued at $123,279,000. Finally, Janus Henderson Group PLC boosted its holdings in Scholar Rock by 26.1% in the first quarter. Janus Henderson Group PLC now owns 2,236,837 shares of the company's stock valued at $109,891,000 after purchasing an additional 462,669 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock, Inc is a biopharmaceutical company focused on developing medicines that selectively target growth factors in their latent forms. The company's approach is designed to modulate the activation of growth factors in specific tissues, with the goal of addressing diseases in which these biological pathways contribute to impaired function or abnormal tissue growth.

Scholar Rock's lead program is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin. The company has studied apitegromab as a potential treatment for spinal muscular atrophy, a genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.